Bio-Rad Laboratories' (NYSE:BIO) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Bio-Rad Laboratories, Inc.'s (NYSE:BIO) stock hasn't moved much. We did some digging, and we found some concerning factors in the details.
The Impact Of Unusual Items On Profit
To properly understand Bio-Rad Laboratories' profit results, we need to consider the US$1.0b gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. We can see that Bio-Rad Laboratories' positive unusual items were quite significant relative to its profit in the year to September 2026. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Bio-Rad Laboratories' Profit Performance
As previously mentioned, Bio-Rad Laboratories' large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Bio-Rad Laboratories' statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. The good news is that it earned a profit in the last twelve months, despite its previous loss. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Bio-Rad Laboratories, you'd also look into what risks it is currently facing. To help with this, we've discovered 2 warning signs (1 is potentially serious!) that you ought to be aware of before buying any shares in Bio-Rad Laboratories.
Today we've zoomed in on a single data point to better understand the nature of Bio-Rad Laboratories' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.